Suchergebnisse - "Cognigni, Valeria"

PubPharm (11)

1

Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer

enthalten in: Anti-cancer drugs | 2024

von Cognigni, V. | Giudice, G. | Bozzetti, F. | +5

2

Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors : A Multicenter Cohort Study

enthalten in: The oncologist | 2024

von Pecci, F. | Cantini, L. | Cognigni, V. | +24

3

Potential immune‑related adverse events during dabrafenib and trametinib treatment : A case series of patients with BRAF V600E melanoma

enthalten in: Molecular and clinical oncology | 2023

von Morgese, F. | Cognigni, V. | Scortichini, L. | +5

4

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer : A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives

enthalten in: Cancers | 2022

von Cognigni, V. | Pecci, F. | Lupi, A. | +5

5

Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak : A Real-World Analysis from the Italian COVID-DELAY Study

enthalten in: The oncologist | 2022

von Mentrasti, G. | Cantini, L. | Zichi, C. | +20

6

BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma

enthalten in: Journal of thoracic disease | 2021

von Murrone, A. | Cantini, L. | Pecci, F. | +14

7

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab

enthalten in: Journal of clinical medicine | 2021

von Lenci, E. | Cantini, L. | Pecci, F. | +17

8

Lynch syndrome-associated lung cancer : pitfalls of an immunotherapy-based treatment strategy in an unusual tumor type

enthalten in: Exploration of targeted anti-tumor therapy | 2021

von Maccaroni, E. | Lenci, E. | Agostinelli, V. | +14

9

Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy : a single center, retrospective, real-world analysis

enthalten in: Exploration of targeted anti-tumor therapy | 2021

von Lenci, E. | Marcantognini, G. | Cognigni, V. | +9

10

Potential benefit of β-glucans as adjuvant therapy in immuno-oncology : a review

enthalten in: Exploration of targeted anti-tumor therapy | 2021

von Cognigni, V. | Ranallo, N. | Tronconi, F. | +2